GOOG: $318.39 ▼ -2.23 (-0.70%)MU: $226.65 ▼ -7.51 (-3.21%)AMD: $215.98 ▼ -1.62 (-0.74%)AVGO: $381.03 ▲ 0.42 (0.11%)LLY: $1,014.49 ▼ -19.07 (-1.85%)LRCX: $157.09 ▼ -2.66 (-1.67%)AMAT: $269.44 ▲ 0.81 (0.30%)MRK: $100.89 ▼ -1.38 (-1.35%)CRM: $247.46 ▲ 8.74 (3.66%)LIN: $403.73 ▼ -5.42 (-1.32%)META: $661.53 ▲ 21.93 (3.43%)NFLX: $103.22 ▼ -0.74 (-0.71%)ORCL: $214.33 ▲ 6.60 (3.18%)USDEUR: $0.86 ▲ 0.00 (0.23%)ARGX.BR: $792.20 ▼ -6.80 (-0.85%)ASML.AS: $957.30 ▼ -6.10 (-0.63%)AZN.L: $13,514.00 ▼ -180.00 (-1.31%)BARC.L: $439.20 ▲ 5.85 (1.35%)BBVA.MC: $19.10 ▲ 0.41 (2.19%)ENR.DE: $117.10 ▲ 3.05 (2.67%)MC.PA: $633.10 ▲ 2.80 (0.44%)RWE.DE: $43.59 ▼ -0.18 (-0.41%)STAN.L: $1,662.00 ▲ 1.50 (0.09%)UCB.BR: $239.90 ▲ 0.10 (0.04%)INTC: $40.50 ▼ -3.26 (-7.45%)XAUUSD: $4,209.06 ▲ 5.94 (0.14%)WBD: $24.54 ▼ -0.03 (-0.12%)WDC: $161.00 ▲ 5.41 (3.48%)IEF: $96.67 ▼ -0.30 (-0.31%)TLT: $88.58 ▼ -0.48 (-0.54%)CAT: $599.15 ▲ 7.66 (1.30%)TMO: $575.24 ▼ -5.21 (-0.90%)AIR.PA: $197.02 ▼ -1.10 (-0.56%)BATS.L: $4,342.00 ▲ 0.00 (0.00%)BP.L: $465.00 ▲ 1.00 (0.22%)CFR.SW: $173.10 ▼ -0.45 (-0.26%)EL.PA: $303.20 ▼ -5.60 (-1.81%)GSK.L: $1,826.00 ▼ -7.00 (-0.38%)LLOY.L: $96.96 ▲ 1.00 (1.04%)RIO.L: $5,494.00 ▼ -10.00 (-0.18%)ROG.SW: $310.10 ▼ -3.70 (-1.18%)AAPL: $280.70 ▼ -3.45 (-1.21%)JNJ: $202.48 ▼ -2.85 (-1.39%)BAYN.DE: $33.58 ▼ -0.68 (-1.97%)GLEN.L: $382.90 ▼ -0.20 (-0.05%)SAN.MC: $9.48 ▲ 0.17 (1.78%)ISRG: $568.63 ▼ -1.08 (-0.19%)IBE.MC: $17.93 ▼ -0.09 (-0.47%)TTE.PA: $57.18 ▲ 0.14 (0.25%)STX: $265.63 ▲ 6.96 (2.69%)AMZN: $229.11 ▼ -3.27 (-1.41%)MSFT: $480.84 ▲ 3.11 (0.65%)NVDA: $183.38 ▲ 3.79 (2.11%)IBB: $172.11 ▼ -0.12 (-0.07%)XBI: $123.25 ▲ 1.42 (1.17%)SOXX: $306.28 ▼ -3.08 (-1.00%)

Company Details

BELLUS Health Inc.

BLU - NASDAQ

Identifiants & Marche

Ticker BLU
ISIN CA07987C2040
CIK 0001259942
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays CA
Siege N/A
Fondee N/A
Site Web Lien

Description

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.